Camelot Portfolios’s Alexion Pharmaceuticals ALXN Stock Holding History

Camelot Portfolios’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,212	Closed	-$1.14M	–	260
2021 Q2	$1.14M	Sell	6,212 -500	-7%	-$85.8K	0.46%	61
2021 Q1	$1.03M	Sell	6,712 -740	-10%	-$114K	0.43%	72
2020 Q4	$1.16M	Buy	7,452 +934	+14%	+$120K	0.61%	53
2020 Q3	$746K	Buy	+6,518	New	+$703K	0.47%	66

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Camelot Portfolios's ALXN Position: Q3 2021 in Review

Camelot Portfolios sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 6,212 shares — an estimated $1.14M sold.

Camelot Portfolios first reported a position in ALXN in Q3 2020 and held it in 4 quarters. The position peaked at $1.16M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Camelot Portfolios reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Camelot Portfolios sold 6,212 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.14M.
Camelot Portfolios first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
Camelot Portfolios's Alexion Pharmaceuticals position peaked at $1.16M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Camelot Portfolios's 13F filing for Q3 2021, filed 4 Nov 2021.